US2014147442A1PendingUtilityA1
Use of il-23 antagonists for treatment of infection
Est. expiryFeb 12, 2027(~0.6 yrs left)· nominal 20-yr term from priority
A61P 31/10A61P 31/20A61K 2039/505A61P 37/02A61K 31/7088C07K 16/2866A61P 37/04A61K 31/713C07K 16/244A61P 31/04A61P 31/18A61P 31/14A61P 31/12A61P 31/00
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.
Claims
exact text as granted — not AI-modified1 . A method of treating a subject having a chronic infection selected from the group consisting of a viral infection, a fungal infection and a bacterial infection, comprising administering an effective amount of an antagonist of IL-23.
2 . (canceled)
3 . The method of claim 1 wherein the chronic infection is a fungal infection.
4 . The method of claim 3 , wherein the fungal infection is selected from the group consisting of candidiasis, aspergillosis, cryptococcosis and onychomycosis.
5 - 9 . (canceled)
10 . The method of claim 1 wherein the chronic infection is a mycobacterial infection.
11 . (canceled)
12 . The method of claim 10 wherein the mycobacterial infection is TB.
13 - 15 . (canceled)
16 . The method of claim 1 wherein the chronic infection is a viral infection caused by a virus selected from the group consisting of HIV, HPV, HBV and HCV.
17 - 20 . (canceled)
21 . A method of enhancing a Th1 immune response in a subject having a chronic infection comprising administering an antagonist of IL-23.
22 . The method of claim 21 wherein the enhanced Th1 immune response comprises a 2-fold or greater increase in the percentage of CD4 + T cells expressing IFN-γ compared with the percentage of CD4 + T cells expressing IFN-γ prior to administering said antagonist of IL-23.
23 . The method of claim 21 wherein the enhanced Th1 immune response comprises a 2-fold or greater decrease in the percentage of CD4 + T cells expressing IL-17 compared with the percentage of CD4 + T cells expressing IL-17 prior to administering said antagonist of IL-23.
24 . (canceled)
25 . The method of claim 1 further comprising administering at least one of an antagonist of IL-17A, IL-6 or TGF-β.
26 - 28 . (canceled)
29 . The method of claim 1 , wherein the antagonist of IL-23 is a binding compound that binds to IL-23p19.
30 . The method of claim 1 , wherein the antagonist of IL-23 is a binding compound that binds to IL-23R.
31 . The method of claim 29 wherein the binding compound is an antibody or antigen binding fragment thereof.
32 . (canceled)
33 . The method of claim 31 wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , a single chain antibody, and a diabody.
34 . The method of claim 31 wherein the antibody is a humanized or fully human antibody or antigen binding fragment thereof.
35 - 38 . (canceled)
39 . The method of claim 1 wherein the antagonist of IL-23 is an siRNA or an antisense nucleic acid.
40 - 41 . (canceled)
42 . The method of claim 1 wherein the subject having the infection is immune compromised.
43 - 50 . (canceled)
51 . The method of claim 30 wherein the binding compound is an antibody or antigen binding fragment thereof.
52 . The method of claim 51 wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , a single chain antibody, and a diabody.
53 . The method of claim 51 wherein the antibody is a humanized or fully human antibody or antigen binding fragment thereof.Join the waitlist — get patent alerts
Track US2014147442A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.